Preclinical Studies

Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary ActionCapsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA SynthesisSecond Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus […]

by

LOS ANGELES–(BUSINESS WIRE)–Phytecs is expanding its preclinical research program on its novel fluorinated cannabidiol, HUF-101, along with its family of related drug molecules developed by noted medicinal chemist and Phytecs Director of Global Research, Prof. Raphael Mechoulam of The Hebrew University of Jerusalem. A new preclinical study found HUF-101 effective in mice models predictive of […]

by

PULLMAN, Wash., July 28 (UPI) — The breakdown of muscle often accompanies chronic or long-term disease, making disease worse and sometimes hastening death, and doctors have no way to stop or slow it. Researchers at Washington State University devised a method of delivering gene therapy to stop muscle wasting without affecting other functions of the […]

by

Click here to receive IBD news via e-mail GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® for spasticity (rigid muscles), recently presented the preliminary top line results from a Phase 2a ulcerative colitis […]

by

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of […]

by

Dublin, Aug. 18, 2016 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of the “Global Silicon Photonics Market 2016-2020” report to their offering. The global silicon photonics market to grow at a CAGR of 48.33% during the period 2016-2020. Global Silicon Photonics Market 2016-2020, has been prepared based on an in-depth market analysis […]

by

MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU) today announced that adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan, the Company’s lead antibody-drug conjugate (ADC) for solid cancer therapy, increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell line. Results from this preclinical study […]

by

A military medical research institute has announced that it plans to move ahead with human testing for a potential Zika vaccine by the end of this year after getting two positive results with laboratory mice. Results from the preclinical study, led by the Walter Reed Army Institute of Research, were published this week in Nature. […]

by

IRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) — Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2016. John McDermott, Endologix Chairman and Chief Executive Officer, said, “We continue to deliver solid revenue growth above expectations and are very […]

by

Alzheimer’s disease is a bastard without a cure. It’s the sixth leading cause of death in America per the Center for Disease Control, and according to the Alzheimer’s Association, 1 in 9 American adults over 65 has it. However, there may be a ray of hope ahead for sufferers and their families. According to observational […]

by

Positive results from two phase 1b studies of ALZ-801 (Alzheon Inc.) have provided the clinical data necessary to move ALZ-801 into a pivotal phase 3 program in patients with Alzheimer’s disease (AD) who are homozygous for the epsilon-4 allele of the apolipoprotein E gene (APOE4/4). ALZ-801 is an “optimized” prodrug of tramiprosate. In 2009, tramiprosate […]

by